The USC Alzheimer’s Therapeutic Research Institute (USC ATRI), located in San Diego, CA, is dedicated to the development of effective treatments for Alzheimer’s disease through innovative, collaborative, multicenter clinical trials. ATRI’s collaboration with Keck investigators, including Drs. Arthur Toga and Paul Thompson at the USC Mark and Mary Stevens Neuroimaging and Informatics Institute, Dr. Helena Chui at the Alzheimer’s Disease Research Center, and Dr. Berislav Zlokovic at the Zilkha Neurogenetic Institute, facilitates rapid progress in data sharing and analytical methods central to the drug development process. USC ATRI is the Keck School’s clinical outlet for testing of new treatments for Alzheimer’s Disease.
Alzheimer’s disease is the sixth leading cause of death in the United States, and the only disease among the top 10 in America that cannot be prevented, cured, or slowed, according to the Alzheimer’s Association.